Drug intelligence / Profile preview

Yushentongluo Granule

Development stage: Unknown
Lead developer: Shanghai Liantang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Yushentongluo Granule is a Traditional Chinese Medicine (TCM) formulation developed by Shanghai General Hospital, specifically designed for the treatment of anovulatory infertility. The formulation is based on TCM principles of nourishing the kidney (Yushen) and dredging the collaterals (Tongluo) to improve ovarian function and promote ovulation. It is often utilized in clinical settings as an adjunctive therapy alongside Western ovulation-inducing agents like clomiphene citrate. The drug aims to regulate the hypothalamic-pituitary-ovarian axis and improve the uterine and ovarian microenvironment to enhance fertility outcomes in women with ovulatory dysfunction.

Brand names: Yushentongluo Granule
Other names: Yushentongluo Keli育肾通络颗粒

Beyond the preview

Go deeper on Yushentongluo Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yushentongluo Granule.

Explore the full profile